Kang Shiwei, Gong Xiaowei, Yuan Yadong
Department of Respiratory and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Epidemiol Infect. 2021 May 12;149:1-26. doi: 10.1017/S0950268821001138.
The aim of this study was to systematically assess the association between smoking and cardiovascular disease (CVD) and disease progression among novel coronavirus pneumonia (coronavirus disease 2019 (COVID-19)) cases. PubMed database and Cochrane Library database were searched by computer to seek the epidemiological data of COVID-19 cases and literatures regarding CVDs from 1 Jan to 6 October 2020. Two researchers independently conducted literature screening, data collection and the assessment of the risk of bias of the studies included. RevMan 5.2 software was employed for meta-analysis. Funnel plot was adopted to assess the publication bias. On the whole, 21 studies comprising 7041 COVID-19 cases were included. As revealed from the meta-analysis, 14.0% (984/7027) of cases had a history of smoking, and 9.7% (675/6931) were subject to underlying CVDs. Cases with a history of smoking achieved a higher rate of COVID-19 disease progression as opposed to those having not smoked (OR 1.53, 95% CI 1.29–1.81, < 0.00001), while no significant association could be found between smoking status and COVID-19 disease progression (OR 1.23, 95% CI 0.93–1.63, = 0.15). Besides, smoking history elevated the mortality rate by 1.91-fold (OR 1.91, 95% CI 1.35–2.69, = 0.0002). Moreover, underlying CVD elevated the incidence of severe disease by 2.87-fold (OR 2.87, 95% CI 2.29–3.61, < 0.00001) and mortality by 3.05-fold (OR 3.05, 95% CI 1.82–5.11, < 0.0001) in COVID-19 cases. As demonstrated from the current evidence, smoking displays a strong association with COVID-19 disease progression and mortality, and intensive tobacco control is imperative. Moreover, cases with CVD show a significantly elevated risk of disease progression and death when subject to COVID-19. However, the association between COVID-19 and CVD, and the potential effect exerted by smoking in the development of the two still require further verifications by larger and higher quality studies.
本研究旨在系统评估新型冠状病毒肺炎(2019冠状病毒病,即COVID-19)病例中吸烟与心血管疾病(CVD)之间的关联以及疾病进展情况。通过计算机检索PubMed数据库和Cochrane图书馆数据库,以获取2020年1月1日至10月6日期间COVID-19病例的流行病学数据以及关于心血管疾病的文献。两名研究人员独立进行文献筛选、数据收集以及对纳入研究的偏倚风险评估。采用RevMan 5.2软件进行荟萃分析。采用漏斗图评估发表偏倚。总体而言,纳入了21项研究,共7041例COVID-19病例。荟萃分析结果显示,14.0%(984/7027)的病例有吸烟史,9.7%(675/6931)患有心血管疾病。有吸烟史的病例COVID-19疾病进展率高于未吸烟病例(比值比[OR] 1.53,95%置信区间[CI] 1.29 - 1.81,P < 0.00001),而吸烟状况与COVID-19疾病进展之间未发现显著关联(OR 1.23,95% CI 0.93 - 1.63,P = 0.15)。此外,吸烟史使死亡率提高了1.91倍(OR 1.91,95% CI 1.35 - 2.69,P = 0.0002)。而且,心血管疾病使COVID-19病例的重症发生率提高了2.87倍(OR 2.87,95% CI 2.29 - 3.61,P < 0.00001),死亡率提高了3.05倍(OR 3.05,95% CI 1.82 - 5.11,P < 0.0001)。根据现有证据表明,吸烟与COVID-19疾病进展和死亡率密切相关,必须加强烟草控制。此外,患有心血管疾病的病例感染COVID-19时疾病进展和死亡风险显著升高。然而,COVID-19与心血管疾病之间的关联以及吸烟在两者发展过程中所起的潜在作用仍需通过更大规模、更高质量的研究进一步验证。